---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-022067"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:55:33.798657+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics Q2 2022 revenue $5.0M, down 82% YoY; net loss $2.7M

## Summary
- Revenue of $5.0M vs $27.4M a year ago; gross profit margin 81.8% due to sales volume inefficiencies.
- Net loss of $2.7M ($0.08 loss per diluted share) compared to net income of $9.8M in Q2 2021.
- Operating loss of $4.1M vs operating income of $11.8M; adjusted EBITDA loss $2.3M.
- Cash, equivalents, and marketable securities at $96.0M as of June 30, 2022.
- Business highlights: Indian JV CoSara cleared for Hepatitis C test; monkeypox test reagents shipped; Co-Dx PCR Home platform optimization continues.

## SEC filing metadata
- accession: 0001493152-22-022067
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315222022067/0001493152-22-022067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315222022067/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-022067
- JSON: https://secwatch.observer/filing/0001493152-22-022067.json
- Plain text: https://secwatch.observer/filing/0001493152-22-022067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.